NCT03976687View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

May 25, 2020

Study Completion Date

May 25, 2020

Conditions
NASH - Nonalcoholic SteatohepatitisHealthy
Interventions
DRUG

EYP001a

Oral tablets

Trial Locations (1)

Unknown

ENYO Pharma clinical site, Randwick

Sponsors

Lead Sponsor

Enyo Pharma
All Listed Sponsors
lead

Enyo Pharma

INDUSTRY